United States Patent 8,580,306 (Drug Patent)
Core invention: Dry size reduction of a soft aerosol dispersion/dissolution-delay additive to an aerodynamic/MMAD target, followed by mixing with active particles and fusing the additive onto active surfaces via compressed milling (ball milling, mechano-fusion, cyclomix, hybridiser, bead/jet/pin/hammer/knife milling, ultracentrifugal milling).
What is patented: scope of the claims
The claims define (1) a method for producing an inhalable composite powder, (2) compositions and inhaler products made by that method, and (3) functional methods (promoting dispersal and delaying dissolution) and (4) therapeutic use.
Method claim set (broad platform)
Claim 1 is the primary platform claim and contains the following required limitations:
- Process steps
- Dry size reduction of additive particles to produce particles with MMAD ≤ 2 μm
- Mixing additive particles with active particles
- Fusing additive particles to surfaces of active particles by compressing the mixture using a milling process selected from:
- ball milling
- mechano-fusion
- cyclomix method
- hybridiser method
- agitator bead milling
- jet milling
- pin milling
- hammer milling
- knife milling
- ultracentrifugal milling
- Additive material constraints
- Additive material is soft, with indentation hardness ≤ 100 MPa
- Additive is suitable for promoting dispersal of active particles upon aerosolisation of a dry powder in a DPIs
- Process constraint
- The reducing step is performed dry (explicitly required in claim 1)
Claims 2-11 add narrower dependent constraints on particle size, additive identity, and physical properties:
- Claim 2: additive particle diameter ≤ 1.5 μm
- Claim 3: additive is hydrophobic, suitable for delaying dissolution in lung
- Claim 4: additive comprises magnesium stearate
- Claim 5: additive comprises a phospholipid
- Claim 6: phospholipid is lecithin
- Claim 7: additive particles are agglomerated
- Claim 8: additive bulk density ≤ 0.4 g/cm³
- Claim 9: additive in flake form with thickness ≤ 0.5 μm
- Claim 10: includes a two-stage approach: start with additive MMAD > 2 μm, reduce to < 2 μm
- Claim 11: active particles are present during the size reduction step of the additive
Product and use claims
Claim 12 creates composition scope:
- A composition for inhalation comprising:
- active substance particles
- additive particles
- Composition must be prepared by the method of claim 1
- Particle size/aerodynamic requirement: aerodynamic diameters in range 2 to 0.05 μm
Claim 13: composition is a powder suitable for a dry powder inhaler
Claim 14: composition further comprises propellant, suitable for a pressurized metered dose inhaler (pMDI)
Claim 15: dry powder inhaler comprising the claim 13 composition
Claim 16: pMDI comprising the claim 14 composition
Claim 17 is a functional method claim closely tracking claim 1 but framed as “promoting dispersal”:
- Reduces additive size to MMAD ≤ 2 μm
- Mixes additive with active
- Fuses additive to active surfaces by compressing via specified milling list
- Requires additive softness: indentation hardness ≤ 100 MPa
- Requires dry size reduction
Claim 18 is a functional dissolution-delay method:
- Reduces additive to MMAD ≤ 2 μm
- Mixes additive with active
- Fuses via the same milling list and compression mechanism
- Requires softness: indentation hardness ≤ 100 MPa
- Requires dry size reduction
- Defines delayed dissolution as relative to dissolution without additive
Claim 19 is therapy method:
- Administration to a human or animal of the claim 12 composition
How broad is the claim coverage (scope map)
Below is a “constraint stack” view: what you must have to infringe each independent hook.
Claim 1 infringement elements (minimum bundle)
- Dry size reduction of additive to produce additive particles with MMAD ≤ 2 μm
- Additive particles mixed with active particles
- Fusing additive to active surfaces by compressing the mixture using one of the specified milling techniques
- Additive is soft (indentation hardness ≤ 100 MPa)
- Additive is suitable for promoting dispersal of active on aerosolisation in a DPI
Claim 12 infringement elements
- You make a composition with:
- active particles
- additive particles
- And you must have used a process that meets claim 1
- Aerodynamic diameter distribution must fall within 2 to 0.05 μm
Claim 17 and 18
- Same process core as claim 1
- Different functional performance framing:
- claim 17: dispersal promotion upon aerosolisation
- claim 18: dissolution delay compared to absence of additive
Where competitors are most likely to run into the patent
The claim structure concentrates protection around a repeatable manufacturing and formulation strategy:
- Particle size spec for additive (MMAD ≤ 2 μm)
- Softness spec (indentation hardness ≤ 100 MPa)
- Dry processing
- Surface fusing via compressed milling
- Milling method list is explicit and wide
- Functional targets: dispersal and delayed dissolution in lungs
From a design-around perspective, the strongest “locked” features are:
- Dry size reduction requirement for the additive
- MMAD threshold (≤ 2 μm)
- Indentation hardness (≤ 100 MPa)
- Compression + fusing by milling (not just mixing)
Claim-by-claim scope: key narrowing levers
The dependent claims create sub-layers that can expand or constrain commercial coverage depending on what a rival uses.
Additive identity and material class
- Magnesium stearate (claim 4)
- Phospholipids, including lecithin (claims 5-6)
- Hydrophobic material for dissolution delay (claim 3)
These provide explicit coverage for common carriers/dispersion aids.
Morphology and physical properties
- Agglomerated additive particles (claim 7)
- Bulk density ≤ 0.4 g/cm³ (claim 8)
- Flake thickness ≤ 0.5 μm (claim 9)
These can matter because companies may try to tune powder behavior via morphology/packing density. The patent ties these traits to the dependent claim scope.
Process timing of active presence
- Additive size reduction can occur:
- separately (implied in base claim 1), or
- with active particles present during reduction (claim 11)
A competitor processing additive alone then blending might avoid claim 11 but still fall under claim 1/17/18 if the rest of the steps are met.
Patent landscape implications (what the claims likely block)
Based on the claim language alone, the protected space is not limited to a single active ingredient or additive brand. It is a manufacturing/formulation method plus composition/product-by-process hooks.
Commercial vectors that are most exposed
- Dry powder inhaler (DPI) formulations using:
- fine additive with MMAD ≤ 2 μm
- soft additive (≤ 100 MPa indentation hardness)
- dry milling of additive followed by fused attachment to active
- pMDI formulations via the same process-derived composition concept (claim 14), though pMDI adds propellant content and the claim recites “prepared by claim 1.”
- “Improved dispersibility” manufacturing protocols that use compressed milling to bind a dispersion aid to carrier/active particle surfaces.
- Delaying dissolution approaches that rely on hydrophobic fine additives and fused surface presentation.
Likely excluded or reduced exposure
The claims leave narrower lanes for design-around because they expressly require:
- dry reduction step
- MMAD ≤ 2 μm for additive particles
- softness by indentation hardness ≤ 100 MPa
- fusing by compression milling using listed techniques
A rival could still have exposure if it meets all those constraints, even if it uses different actives.
Key points for freedom-to-operate screening
The claims point to a checklist that will identify whether a product or manufacturing route is within the asserted scope.
Checklist tied to claim language
- Additive size reduced to MMAD ≤ 2 μm
- Size reduction is performed dry
- Additive is soft with indentation hardness ≤ 100 MPa
- Additive fused onto active surfaces using a milling method from the explicit list with compressing of the mixture
- Final composition meets aerodynamic range 2 to 0.05 μm
- For functional protection: dispersal promotion (claim 17) and/or delayed dissolution (claim 18) are claimed as outcomes tied to the method
Tables
Table 1: Independent claim coverage
| Claim |
Category |
What must be true (high-level) |
| 1 |
Method |
Dry size reduction of soft additive to MMAD ≤ 2 μm; mix with active; fuse additive to active surfaces by compressed milling using listed equipment/methods; additive promotes DPI dispersal |
| 12 |
Composition |
Composition made by method of claim 1; aerodynamic diameters 2 to 0.05 μm; active + additive |
| 17 |
Method (dispersal) |
Same process core as claim 1; framed around promoting dispersal on aerosolisation |
| 18 |
Method (dissolution delay) |
Same process core as claim 1; framed around delaying dissolution versus absence of additive |
| 19 |
Therapy |
Administer claim 12 composition to human/animal |
Table 2: Dependent claims that add or refine scope
| Dependent claim |
Added requirement |
| 2 |
additive diameter ≤ 1.5 μm |
| 3 |
additive is hydrophobic and delays dissolution in lung |
| 4 |
additive comprises magnesium stearate |
| 5 |
additive comprises a phospholipid |
| 6 |
additive is lecithin |
| 7 |
additive particles are agglomerated |
| 8 |
additive bulk density ≤ 0.4 g/cm³ |
| 9 |
additive flakes, thickness ≤ 0.5 μm |
| 10 |
start with additive MMAD > 2 μm; reduce to < 2 μm |
| 11 |
active present during additive size reduction |
| 13 |
composition is powder for DPI |
| 14 |
composition includes propellant for pMDI |
| 15-16 |
inhaler product claims for DPI and pMDI compositions |
| (Implicit across 1/17/18) |
additive softness ≤ 100 MPa indentation hardness; dry reduction; fusion via compressing milling |
What to treat as hard boundaries in claim construction
- “Performed dry” is explicit and limits process variants that use wet comminution or solvent-assisted treatment for the additive size reduction.
- MMAD ceiling of 2 μm for additive after size reduction is a numeric boundary; the dependent claims tighten diameter (≤1.5 μm), but base claim anchors at MMAD ≤2 μm.
- Indentation hardness ≤100 MPa anchors “soft” in a measurable property, tightening scope to materials with sufficiently low mechanical resistance.
- “Fusing the particles … to the surfaces” plus “compressing … using a milling process selected from…” indicates an attachment mechanism requiring mechanical action beyond simple blending.
Key Takeaways
- US 8,580,306 protects a dry, size-reduced, soft additive strategy where additive particles with MMAD ≤ 2 μm are produced dry, mixed with active particles, and fused to active surfaces via compressed milling selected from an explicit list.
- Coverage expands from the manufacturing method (claims 1, 17, 18) into composition and inhaler products (claims 12-16) via a product-by-process concept tied to the claim 1 method and an aerodynamic size window (2 to 0.05 μm).
- Dependent claims add material and morphology specificity (magnesium stearate, lecithin/phospholipids, hydrophobic dissolution delay, agglomerated particles, low bulk density, flake thickness) that can narrow or strengthen infringement arguments depending on actual formulation choices.
- Hard technical screening points for FTO are: dry reduction, MMAD ≤ 2 μm for additive, indentation hardness ≤ 100 MPa, and compressed milling fusion to active surfaces.
FAQs
-
Does claim 1 require the additive to be magnesium stearate or lecithin?
No. Magnesium stearate (claim 4) and lecithin (claims 5-6) are dependent. Claim 1 covers any soft additive meeting indentation hardness ≤100 MPa and dispersal suitability, with dry reduction and fusion by compressed milling.
-
Can the milling step use any type of equipment, or only what is listed?
Only the milling processes expressly listed in the claim text satisfy the limitation.
-
Is the “dry” limitation limited to the size reduction step or the entire process?
The claim language specifies that the reducing step is performed dry. The milling/fusing steps follow by compressing using the selected milling process, but the “dry” restriction is explicitly tied to reduction.
-
What does claim 12 add beyond claim 1?
Claim 12 creates a composition claim requiring aerodynamic particle diameters 2 to 0.05 μm and requiring that the composition is prepared by the method of claim 1.
-
How do claims 17 and 18 differ if the manufacturing process is the same?
They differ by claimed performance outcome framing: claim 17 targets promoting dispersal upon aerosolisation, while claim 18 targets delaying dissolution compared to the active alone.
References (APA)
[1] United States Patent No. 8,580,306.
